These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30457960)

  • 21. Correlates of Skin and Soft Tissue Infections in Injection Drug Users in a Syringe-Exchange Program in Malmö, Sweden.
    Dahlman D; Håkansson A; Björkman P; Blomé MA; Kral AH
    Subst Use Misuse; 2015; 50(12):1529-35. PubMed ID: 26583450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Polydrug and Psychosocial Profile of Synthetic Cannabinoid Use in a New York City Community Sample, 2016-2017.
    Joseph A; Lekas HM; Manseau M; Lewis C
    Subst Use Misuse; 2019; 54(2):282-287. PubMed ID: 30526203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adults who misuse opioids: Substance abuse treatment use and perceived treatment need.
    Choi NG; DiNitto DM; Marti CN; Choi BY
    Subst Abus; 2019; 40(2):247-255. PubMed ID: 30810503
    [No Abstract]   [Full Text] [Related]  

  • 24. An Internet Snapshot Survey Assessing the sale of Synthetic Cannabinoid Receptor Agonists for use with Electronic Vaping Devices.
    Gould A; Dargan PI; Wood DM
    J Med Toxicol; 2024 Jul; 20(3):271-277. PubMed ID: 38839732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
    Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
    Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.
    Bonar EE; Ashrafioun L; Ilgen MA
    Drug Alcohol Depend; 2014 Oct; 143():268-71. PubMed ID: 25096272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
    Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
    Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
    Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
    Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
    Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
    Clin Toxicol (Phila); 2024 Jun; 62(6):378-384. PubMed ID: 38934347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure.
    Janssens LK; Sommer MJ; Grafinger KE; Hermanns-Clausen M; Auwärter V; Stove CP
    Arch Toxicol; 2024 Oct; 98(10):3337-3350. PubMed ID: 39115690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
    Pizzicato LN; Johnson CC; Viner KM
    Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
    [No Abstract]   [Full Text] [Related]  

  • 33. Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users.
    Smith KE; Bunting AM; Walker R; Hall MT; Grundmann O; Castillo O
    J Psychoactive Drugs; 2019; 51(4):311-322. PubMed ID: 30961450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of persons who inject drugs and who witness opioid overdoses in Vietnam: a cross-sectional analysis to inform future overdose prevention programs.
    Blackburn NA; Lancaster KE; Ha TV; Latkin CA; Miller WC; Frangakis C; Chu VA; Sripaipan T; Quan VM; Minh NL; Vu PT; Go VF
    Harm Reduct J; 2017 Sep; 14(1):62. PubMed ID: 28882143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
    Alam RM; Keating JJ
    Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of obesity among U.S. population with substance dependence.
    Hu L; Oden N; Tai B; VanVeldhuisen P
    Drug Alcohol Depend; 2020 Dec; 217():108293. PubMed ID: 32980787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison.
    Ralphs R; Williams L; Askew R; Norton A
    Int J Drug Policy; 2017 Feb; 40():57-69. PubMed ID: 27955961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of psychotic symptoms in substance users: a comparison across substances.
    Smith MJ; Thirthalli J; Abdallah AB; Murray RM; Cottler LB
    Compr Psychiatry; 2009; 50(3):245-50. PubMed ID: 19374969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homelessness and psychiatric admission rates through the criminal justice system.
    James DV; Farnham F; Cripps J
    Lancet; 1999 Apr; 353(9159):1158. PubMed ID: 10209991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.